Education
About Us
Working with TipRanks
Follow Us
Modalis Therapeutics Corporation (JP:4883)
:4883
RESEARCH TOOLSreports
4883 Stock Chart & Stats
Day’s Range― - ―
52-Week Range¥66.00 - ¥203.00
Previous CloseN/A
Volume5.80M
Average Volume (3M)7.40M
Market Cap
¥6.54B
Enterprise Value¥54.90B
Total Cash (Recent Filing)¥3.58B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Aug 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.02
Shares Outstanding76,928,200
10 Day Avg. Volume11,194,629
30 Day Avg. Volume7,402,616
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-4.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Modalis Therapeutics Corporation News
PremiumCompany Announcements
Modalis Therapeutics Issues New Shares for Employee Compensation
PremiumCompany Announcements
Modalis Completes New Share Issuance for Employee Remuneration
PremiumCompany Announcements
Modalis Therapeutics Issues New Shares for Stock-Based Remuneration
PremiumCompany Announcements
Modalis Therapeutics Named Finalist in XPRIZE Healthspan CompetitionPremiumCompany Announcements
Modalis Therapeutics Reports Foreign Exchange Loss in Q1 2025
PremiumCompany Announcements
Modalis Completes New Share Issuance for Employee Remuneration
PremiumCompany Announcements
Modalis Therapeutics Announces Terms for 16th Stock Option Program4883 FAQ
What was Modalis Therapeutics Corporation’s price range in the past 12 months?
Modalis Therapeutics Corporation lowest stock price was ¥66.00 and its highest was ¥203.00 in the past 12 months.
What is Modalis Therapeutics Corporation’s market cap?
Modalis Therapeutics Corporation’s market cap is ¥6.54B.
When is Modalis Therapeutics Corporation’s upcoming earnings report date?
Modalis Therapeutics Corporation’s upcoming earnings report date is Aug 01, 2025 which is in 36 days.
How were Modalis Therapeutics Corporation’s earnings last quarter?
Modalis Therapeutics Corporation released its earnings results on May 08, 2025. The company reported -¥9.02 earnings per share for the quarter, missing the consensus estimate of N/A by -¥9.02.
Is Modalis Therapeutics Corporation overvalued?
According to Wall Street analysts Modalis Therapeutics Corporation’s price is currently Overvalued.
Does Modalis Therapeutics Corporation pay dividends?
Modalis Therapeutics Corporation does not currently pay dividends.
What is Modalis Therapeutics Corporation’s EPS estimate?
Modalis Therapeutics Corporation’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modalis Therapeutics Corporation have?
Modalis Therapeutics Corporation has 76,928,200 shares outstanding.
What happened to Modalis Therapeutics Corporation’s price movement after its last earnings report?
Modalis Therapeutics Corporation reported an EPS of -¥9.02 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.667%.
Which hedge fund is a major shareholder of Modalis Therapeutics Corporation?
Currently, no hedge funds are holding shares in JP:4883
Company Description
Modalis Therapeutics Corporation
Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. It is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology that enables to control gene expressions through modulating the switch (epigenetics of a specific locus. The company has a. joint research agreement with JCR Pharmaceuticals Co., Ltd. to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was founded in 2016 and is headquartered in Tokyo, Japan.
Technical Analysis
Solasia Pharma KK
―
Nippon Chemiphar Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Medrx Co., Ltd.
―
Cyfuse Biomedical K.K.
―